HLS Therapeutics Inc. (TSX:HLS)

HLS Therapeutics Ratios and Metrics

Market cap in millions CAD. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 2, 2026	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	141	125	127	318	487	571
Market Cap Growth	4.89%	-1.37%	-60.20%	-34.60%	-14.81%	-27.86%
Enterprise Value	201	194	220	426	586	692
Last Close Price	4.50	3.93	3.95	9.69	14.56	17.28
Forward PE	-	-	-	-	-	20.62
PS Ratio	1.81	1.53	1.52	3.83	6.41	7.99
PB Ratio	1.64	1.22	0.98	1.88	2.39	2.65
P/FCF Ratio	7.41	10.87	6.09	13.92	23.48	48.18
P/OCF Ratio	7.31	10.85	6.08	13.88	23.41	47.99
EV/Sales Ratio	2.58	2.38	2.64	5.12	7.71	9.67
EV/EBITDA Ratio	8.42	8.99	7.74	15.14	19.78	26.32
EV/FCF Ratio	10.58	16.88	10.57	18.63	28.26	58.31
Debt / Equity Ratio	0.88	0.93	0.90	0.78	0.61	0.65
Debt / EBITDA Ratio	3.15	4.42	4.06	4.66	4.07	5.17
Debt / FCF Ratio	3.97	8.32	5.56	5.76	5.96	11.73
Net Debt / Equity Ratio	0.70	0.69	0.67	0.61	0.48	0.52
Net Debt / EBITDA Ratio	2.53	3.27	3.05	3.68	3.26	4.29
Net Debt / FCF Ratio	3.18	6.13	4.17	4.54	4.66	9.51
Asset Turnover	0.36	0.31	0.28	0.24	0.21	0.18
Inventory Turnover	2.13	1.58	1.43	1.20	0.99	1.43
Quick Ratio	0.81	1.11	1.22	1.02	1.18	0.93
Current Ratio	1.17	1.57	1.65	1.42	1.58	1.29
Return on Equity (ROE)	-20.02%	-23.25%	-24.69%	-16.50%	-7.95%	-8.82%
Return on Assets (ROA)	-1.86%	-2.60%	-2.87%	-3.26%	-1.35%	-2.42%
Return on Capital Employed (ROCE)	-4.00%	-5.60%	-5.70%	-6.40%	-2.50%	-4.50%
Earnings Yield	-13.97%	-22.63%	-28.70%	-10.03%	-3.41%	-3.42%
FCF Yield	13.50%	9.20%	16.42%	7.18%	4.26%	2.08%
Dividend Yield	-	-	2.53%	2.06%	1.37%	1.16%
Buyback Yield / Dilution	0.81%	1.31%	0.52%	-0.77%	-1.48%	-8.01%
Total Shareholder Return	0.81%	1.31%	3.06%	1.29%	-0.11%	-6.86%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.